Detection of Mycoplasma pneumoniae Nucleic Acid and Drug Resistance Gene.

IF 1.2 4区 综合性期刊 Q3 MULTIDISCIPLINARY SCIENCES
Yunxia Wang, Chunling Xue, Qiuying Luo, Jianhong Ma, Xiangxing Zeng
{"title":"Detection of Mycoplasma pneumoniae Nucleic Acid and Drug Resistance Gene.","authors":"Yunxia Wang, Chunling Xue, Qiuying Luo, Jianhong Ma, Xiangxing Zeng","doi":"10.3791/68500","DOIUrl":null,"url":null,"abstract":"<p><p>Mycoplasma pneumoniae (Mp) represents one of the most prevalent pathogens responsible for community-acquired pneumonia (CAP) in pediatric populations. The detection of Mycoplasma pneumoniae resistance genes provides robust technical support and a theoretical foundation for the precise clinical diagnosis and treatment of MP infections. Accurate diagnosis and evaluation of drug resistance in Mp infection are essential for clinical treatment. Common detection methods for Mycoplasma pneumoniae include culture, antibody detection, and molecular biology-based assays. Mp culture is the gold standard for diagnosis but requires a specific medium, is time-consuming, and has low sensitivity. Antibody-based detection of Mp is widely used; however, false negatives may occur in the early stage of infection. Molecular biology-based detection provides rapid turnaround, low risk of contamination, high sensitivity, high specificity, and is not limited by the timing of sample collection or immune status. It has therefore been recognized as a new gold standard for diagnosing Mycoplasma pneumoniae infection. Macrolide agents are the first-choice treatment for Mp infection in children. However, with the extensive use of macrolides in respiratory tract infections in children, the incidence of drug-resistant Mycoplasma pneumoniae infection has been increasing. Patients infected with resistant strains experience significantly longer fever duration, extended hospitalization, and prolonged fever after administration compared with those infected with sensitive strains. Mutation sites identified to date include 2063, 2064, 2067, and 2617. In China, point mutations have been documented only at positions 2063 and 2064, with an A-to-G substitution at position 2063 being the most common. For these sites, polymerase chain reaction (PCR) combined with fluorescent probe technology has been employed to detect the nucleic acids and drug resistance mutations of Mycoplasma pneumoniae in human sputum samples. Detection of Mycoplasma pneumoniae resistance genes offers crucial technical support and a theoretical basis for accurate diagnosis and effective treatment of Mp infection.</p>","PeriodicalId":48787,"journal":{"name":"Jove-Journal of Visualized Experiments","volume":" 223","pages":""},"PeriodicalIF":1.2000,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Jove-Journal of Visualized Experiments","FirstCategoryId":"103","ListUrlMain":"https://doi.org/10.3791/68500","RegionNum":4,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}
引用次数: 0

Abstract

Mycoplasma pneumoniae (Mp) represents one of the most prevalent pathogens responsible for community-acquired pneumonia (CAP) in pediatric populations. The detection of Mycoplasma pneumoniae resistance genes provides robust technical support and a theoretical foundation for the precise clinical diagnosis and treatment of MP infections. Accurate diagnosis and evaluation of drug resistance in Mp infection are essential for clinical treatment. Common detection methods for Mycoplasma pneumoniae include culture, antibody detection, and molecular biology-based assays. Mp culture is the gold standard for diagnosis but requires a specific medium, is time-consuming, and has low sensitivity. Antibody-based detection of Mp is widely used; however, false negatives may occur in the early stage of infection. Molecular biology-based detection provides rapid turnaround, low risk of contamination, high sensitivity, high specificity, and is not limited by the timing of sample collection or immune status. It has therefore been recognized as a new gold standard for diagnosing Mycoplasma pneumoniae infection. Macrolide agents are the first-choice treatment for Mp infection in children. However, with the extensive use of macrolides in respiratory tract infections in children, the incidence of drug-resistant Mycoplasma pneumoniae infection has been increasing. Patients infected with resistant strains experience significantly longer fever duration, extended hospitalization, and prolonged fever after administration compared with those infected with sensitive strains. Mutation sites identified to date include 2063, 2064, 2067, and 2617. In China, point mutations have been documented only at positions 2063 and 2064, with an A-to-G substitution at position 2063 being the most common. For these sites, polymerase chain reaction (PCR) combined with fluorescent probe technology has been employed to detect the nucleic acids and drug resistance mutations of Mycoplasma pneumoniae in human sputum samples. Detection of Mycoplasma pneumoniae resistance genes offers crucial technical support and a theoretical basis for accurate diagnosis and effective treatment of Mp infection.

肺炎支原体核酸及耐药基因检测。
肺炎支原体(Mp)是儿科人群中引起社区获得性肺炎(CAP)的最常见病原体之一。肺炎支原体耐药基因的检测为MP感染的临床精准诊断和治疗提供了强有力的技术支持和理论基础。准确诊断和评估Mp感染的耐药性对临床治疗至关重要。肺炎支原体的常见检测方法包括培养、抗体检测和基于分子生物学的检测。Mp培养是诊断的金标准,但需要特定的培养基,耗时,灵敏度低。基于抗体的Mp检测被广泛应用;然而,在感染的早期阶段可能会出现假阴性。基于分子生物学的检测提供快速周转,低污染风险,高灵敏度,高特异性,并且不受样品采集时间或免疫状态的限制。因此,它已被公认为诊断肺炎支原体感染的新金标准。大环内酯类药物是儿童Mp感染的首选治疗药物。然而,随着大环内酯类药物在儿童呼吸道感染中的广泛应用,耐药肺炎支原体感染的发生率不断上升。与感染敏感菌株的患者相比,感染耐药菌株的患者在给药后发烧持续时间明显更长,住院时间延长,发烧时间延长。迄今为止确定的突变位点包括2063、2064、2067和2617。在中国,仅记录到位点2063和2064的点突变,位点2063的a到g替换是最常见的。针对这些位点,采用聚合酶链反应(PCR)结合荧光探针技术检测人痰标本中肺炎支原体的核酸及耐药突变。肺炎支原体耐药基因的检测为Mp感染的准确诊断和有效治疗提供了重要的技术支持和理论基础。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Jove-Journal of Visualized Experiments
Jove-Journal of Visualized Experiments MULTIDISCIPLINARY SCIENCES-
CiteScore
2.10
自引率
0.00%
发文量
992
期刊介绍: JoVE, the Journal of Visualized Experiments, is the world''s first peer reviewed scientific video journal. Established in 2006, JoVE is devoted to publishing scientific research in a visual format to help researchers overcome two of the biggest challenges facing the scientific research community today; poor reproducibility and the time and labor intensive nature of learning new experimental techniques.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信